Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

ClinicalTrials.gov ID: NCT00675844

Public ClinicalTrials.gov record NCT00675844. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48 Weeks in Participants Who Have Completed 96 Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.

Study identification

NCT ID
NCT00675844
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Enrollment
7 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2008
Primary completion
Feb 28, 2010
Completion
Feb 28, 2010
Last update posted
Aug 13, 2023

2008 – 2010

United States locations

U.S. sites
5
U.S. states
3
U.S. cities
5
Facility City State ZIP Site status
Clinical Trial Site Orlando Florida 32803
Clinical Trial Site Pensacola Florida 32504
Clinical Trial Site Newark New Jersey 07102
Clinical Trial Site Austin Texas 78705
Clinical Trial Site Dallas Texas 75204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00675844, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 13, 2023 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00675844 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →